# US 2026/0098262 A9 · Compounds and methods for skipping exon 44 in duchenne muscular dystrophy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0098262 A9
- Document ID: US20260098262A9
- Status: Published application
- Kind: A9
- Application number: 18/688,083
- Filed: 2022-08-30
- Published: 2026-04-09
- Earliest claimed: 2021-09-01
- Assignees: Entrada Therapeutics, Inc.
- Applicants: Entrada Therapeutics, Inc.
- Inventors: Xiang Li; Ziqing Qian; Mahboubeh Kheirabadi; Mark Wysk; Natarajan Sethuraman; Wenlong Lian; Mahsweta Girgenrath; Nelsa Estrella
- Web page: https://patentgrep.com/patent/US20260098262A9

## CPC

- C07K 7/64: Cyclic peptides containing only normal peptide links
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61K 47/6455: {Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids}
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 2310/11: Antisense
- C12N 2310/3233: Morpholino-type ring
- C12N 2310/3513: Protein; Peptide
- C12N 2320/32: Special delivery means, e.g. tissue-specific
- C12N 2320/33: Alteration of splicing
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Described herein in various embodiments are compositions comprising (a) a cyclic peptide; and (b) an antisense compound, wherein the antisense compound targets exon 44 of the DMD gene in a pre-mRNA sequence.

## Claims

### Claim at position 1

1-58. (canceled)

### Claim 59

A compound comprising an Endosomal Escape Vehicle (EEV) conjugated to a therapeutic moiety comprising an antisense compound (AC) that is complementary to a target sequence comprising at least a portion of exon 44 of DMD gene in a pre-mRNA sequence; wherein the EEV comprises:
(a) a cyclic peptide of formula:
or a protonated form thereof,
wherein
R1, R2, and R3 are each independently H or a side chain comprising an aryl or heteroaryl group;
at least two of R1, R2, and R3 are a side chain of phenylalanine;
AASC is an amino acid side chain;
R4 and R7 are independently H or an amino acid side;
each m is independently an integer from 0-3; and
q is an integer from 1-4;
(b) an exocyclic peptide (EP) comprising from 2 to 10 amino acid residues, wherein 1 or 2 amino acid residues comprise a side chain of a guanidine group, or a protonated form thereof or 2, 3, or 4 lysine residues;
(c) a linker comprising:
(i) a —(OCH2CH2)z— subunit, wherein z′ is an integer from 1 to 23;
(ii) one or more amino acid residues, such as a residue of glycine, β-alanine, 4-aminobutyric acid, 5-aminopentoic acid or 6-aminohexanoic acid, or combinations thereof; or
(iii) combinations of (i) and (ii).

### Claim 60 (depends on 59)

The compound of claim 59, wherein the AC comprises a phosphorodiamidate morpholino nucleotide (PMO) comprising 15-30 nucleotides.

### Claim 61 (depends on 59)

The compound of claim 59, wherein the cyclic peptide is conjugated to the 3′ end of the AC, the 5′ end of the AC, or the backbone of the AC.

### Claim 62 (depends on 59)

The compound of claim 59, wherein the linker conjugates the cyclic peptide to the AC.

### Claim 63 (depends on 59)

The compound of claim 59, wherein the AC comprises a sequence with at least 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to a sequence comprising 5′-XGAAAACGCCGCCAXXXCXCAACAGAXCXG-3′, wherein X is U or T, or a portion thereof.

### Claim 64 (depends on 59)

The compound of claim 59, wherein the AC comprises a sequence with at least 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to a sequence comprising 5′-AAA CGC CGC CAT TTC TCA ACA GAT C-3′ or 5′-T GTT CAG CTT CTG TTA GCC ACT G AT-3′.

### Claim 65 (depends on 64)

The compound of claim 64, wherein the AC comprises a sequence comprising at least 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 contiguous nucleotides of a base sequence comprising: 5′-AAA CGC CGC CAT TTC TCA ACA GAT C-3′ or 5′-T GTT CAG CTT CTG TTA GCC ACT G AT-3′.

### Claim 66 (depends on 59)

The compound of claim 59, wherein the AC has a sequence comprising:
a)
5′-GGCCAAACCTCGGCTTACTG AAAT-3′;
b)
5′-GGCCAAACCTCGGCTTACCTGAAAT-3′;
c)
5′-TGAAAACGCCGCCATTTCTCAACAGATCTG-3′;
d)
5′-TGAAAACGCCGCCATTTCTCAACAG-3′;
e)
5′-AAACGCCGCCATTTCTCAACAGATC-3′;
f)
5′-AACGCCGCCATTTCTCAACAGATCT-3′;
g)
5′-CCGCCATTTCTCAACAGATCTGTCA-3′;
h)
5′-TGTTCAGCTTCTGTTAGCCACTGAT-3′;
i)
5′-ACTGTTCAGCTTCTGTTAGCCACTG-3′;
or any reverse complement thereof.

### Claim 67 (depends on 59)

The compound of claim 59, wherein the linker is of formula:
wherein
x is an integer from 1-23;
y is an integer from 1-5;
z is an integer from 1-23;
*is the point of attachment to the AASC; and
M is a bonding group.

### Claim 68 (depends on 59)

The compound of claim 59, wherein M comprises
wherein t′ is an integer from 0 to 10.

### Claim 69 (depends on 59)

The compound of claim 59, wherein R4 and R7 are independently an amino acid side chain of citrulline or serine.

### Claim 70 (depends on 59)

The compound of claim 59, wherein:
(i) the exocyclic peptide comprises 1 or 2 amino acid residues comprising a side chain comprising a guanidine group, or a protonated form thereof;
(ii) the exocyclic peptide comprises 2, 3, or 4 lysine residues; and
(iii) the exocyclic peptide comprises at least 2 amino acid residues with a hydrophobic side chain, for example wherein the hydrophobic side chain is selected from valine, proline, alanine, leucine, isoleucine, and methionine.

### Claim 71 (depends on 59)

The compound of claim 59, wherein the EP has the structure: Ac-PKKKRKV.

### Claim 72 (depends on 59)

The compound of claim 59, wherein the cyclic peptide comprises:
or a protonated form thereof,
wherein,
one of R1, R2, and R3 is H;
two of R1, R2, and R3 are CH2Ph;
R4 and R7 are independently H or an amino acid side chain;
AASC is an amino acid side chain;
q is 1, 2, 3 or 4; and
each m is independently an integer 0, 1, 2, or 3.

### Claim 73 (depends on 59)

The compound of claim 59, wherein the cyclic peptide comprises:
or a protonated form thereof,
wherein
R1, R2, and R3 are —CH2Ph;
R4 and R7 are independently H or an amino acid side chain;
AAsc is an amino acid side chain;
q is 1, 2, 3 or 4; and
each m is independently an integer 0, 1, 2, or 3.

### Claim 74 (depends on 59)

The compound of claim 59, wherein the cyclic peptide comprises:
or a protonated form thereof,
wherein,
R1, R2, and R3 are each independently a side chain comprising an aryl or heteroaryl group;
at least two of R1, R2, and R3 are a side chain of phenylalanine;
AASC is an amino acid side chain;
R4 and R7 are independently H or an amino acid side chain of serine or citrulline
q is 1, 2, 3 or 4; and
each m is independently an integer 0, 1, 2, or 3.

### Claim 75 (depends on 59)

The compound of claim 59, wherein the cyclic peptide is selected from Ff-Nal-GrGrQ; Ff-Nal-GRGRQ; FfFGRGRQ; FGFGRGRQ; CfFGrGrQ; FGFGRRRQ; and FGFRRRRQ.

### Claim 76 (depends on 59)

The compound of claim 59, wherein the EEV has the formula:
Ac-PKKKRKV-PEGx-K(cyclo[FGFGRGRQ])-PEGy-K(N3)—NH2;
Ac-PKKKRKV-PEGx-K(cyclo[FGFGRGRQ])-PEGy-OH;
Ac-PKKKRKV-PEGx-K(cyclo[GfFGrGrQ])-PEGy-K(N3)—NH2;
Ac-PKKKRKV-PEGx-K(cyclo[GfFGrGrQ])-PEGy-OH;
Ac-PKKKRKV-PEGx-K(cyclo[FfFGRGRQ])-PEGy-K(N3)—NH2;
Ac-PKKKRKV-PEGx-K(cyclo[FfFGRGRQ])-PEGy-OH;
Ac-PKKKRKV-PEGx-K(cyclo[Ff-Nal-GrGrQ])-PEGy-K(N3)—NH2; or
Ac-PKKKRKV-PEGx-K(cyclo[Ff-Nal-GrGrQ])-PEGy-OH;
prior to conjugation to the therapeutic moiety.

### Claim 77 (depends on 59)

The compound of claim 59, wherein the EEV has the formula:
Ac-PKKKRKV-PEG2-K(cyclo[FGFGRGRQ])-PEG2-K(N3)—NH2;
Ac-PKKKRKV-PEG2-K(cyclo[FGFGRGRQ])-PEG12-K(N3)—NH2;
Ac-PKKKRKV-PEG2-K(cyclo[FGFGRGRQ])-PEG2-OH; or
Ac-PKKKRKV-PEG2-K(cyclo[FGFGRGRQ])-PEG12-OH;
Ac-PKKKRKV-PEG2-K(cyclo[GfFGrGrQ])-PEG2-K(N3)—NH2;
Ac-PKKKRKV-PEG2-K(cyclo[GfFGrGrQ])-PEG12-K(N3)—NH2;
Ac-PKKKRKV-PEG2-K(cyclo[GfFGrGrQ])-PEG2-OH;
Ac-PKKKRKV-PEG2-K(cyclo[GfFGrGrQ])-PEG12-OH;
Ac-PKKKRKV-PEG2-K(cyclo[FfFGRGRQ])-PEG2-K(N3)—NH2;
Ac-PKKKRKV-PEG2-K(cyclo[FfFGRGRQ])-PEG12-K(N3)—NH2;
Ac-PKKKRKV-PEG2-K(cyclo[FfFGRGRQ])-PEG2-OH;
Ac-PKKKRKV-PEG2-K(cyclo[FfFGRGRQ])-PEG12-OH,
Ac-PKKKRKV-PEG2-K(cyclo[Ff-Nal-GrGrQ])-PEG2-K(N3)—NH2;
Ac-PKKKRKV-PEG2-K(cyclo[Ff-Nal-GrGrQ])-PEG12-K(N3)—NH2;
Ac-PKKKRKV-PEG2-K(cyclo[Ff-Nal-GrGrQ])-PEG2-OH;
Ac-PKKKRKV-PEG2-K(cyclo[Ff-Nal-GrGrQ])-PEG12-OH;
Ac-PKKKRKV-PEG2-K(cyclo[FfΦ-Cit-r-Cit-r-Q])-PEG12-K(N3)—NH2;
Ac-PKKKRKV-K(cyclo[FfΦ-R-r-Cit-rQ])-PEG12-K(N3)—NH2;
Ac-PKKKRKV-K(cyclo[FfΦ-Cit-r-R-rQ])-PEG12-K(N3)—NH2;
Ac-PKKKRKV-K(cyclo[FfΦR-cit-R-cit-Q])-PEG12-K(N3)—NH2;
Ac-PKKKRKV-PEG2-K(cyclo[FfΦ-Cit-r-Cit-rQ])-PEG2-k(N3)—NH2;
Ac-PKKKRKV-PEG2-K(cyclo[FfΦ-Cit-r-Cit-rQ])-PEG4-k(N3)—NH2;
Ac-PKKKRKV-K(cyclo[FfΦ-Cit-r-Cit-rQ])-PEG12-k(N3)—NH2;
Ac-PKKKRKV-PEG2-K(cyclo[FfΦ-Cit-r-Cit-r-Q])-PEG12-k(N3)—NH2; or
Ac-PKKKRKV-PEG2-K(cyclo[FfΦ-Cit-r-Cit-r-Q])-PEG12-K(N3)—NH2;
prior to conjugation to the therapeutic moiety.

### Claim 78 (depends on 59)

The compound of claim 59, wherein the EEV has the formula:
Ac-PKKKRKV-PEG2-K(cyclo[FGFGRGRQ])-PEG12-OH;
Ac-PKKKRKV-PEG2-K(cyclo[FGFGRGRQ])-PEG2-K(N3)—NH2;
Ac-PKKKRKV-PEG2-K(cyclo[GfFGrGrQ])-PEG12-OH;
Ac-PKKKRKV-PEG2-K(cyclo[GfFGrGrQ])-PEG2-K(N3)—NH2;
Ac-PKKKRKV-K(cyclo[Ff-Nal-RrRrQ])-PEG12-K(N3)—NH2;
Ac-PKKKRKV-PEG2-K(cyclo[FfFGRGRQ])-PEG2-K(N3)—NH2;
Ac-PKKKRKV-K(cyclo([Ff-Nal-GrGrQ])-PEG12-K(N3)—NH2; or
Ac-PKKKRKV-PEG2-K(cyclo[Ff-Nal-GrGrQ])-PEG12-OH;
prior to conjugation to the therapeutic moiety.
